Key points are not available for this paper at this time.
The Recurrence Score test is validated to predict clinical response to neoadjuvant letrozole in postmenopausal patients with ER+, HER2-negative, clinically node-negative breast cancer.
Iwata et al. (Fri,) studied this question.